Dr. Gregory Weinhoff is Chief Business Officer of Centessa Pharmaceuticals. Before taking on the role of CBO, Greg served as Chief Financial Officer of Centessa from March 2021 to June 2024. Previously, Greg was a Co-Founder and Chief Financial and Chief Business Officer at Arvelle Therapeutics BV. In that role, he was responsible for sourcing cenobamate, a novel anti-seizure medicine with best-in-class efficacy, negotiating the license with SK Biopharmaceuticals for European rights, and raising a $207.8M start-up financing, which was one of the largest start-up financings for a European biopharma. Greg played a key role in preparing the Arvelle organization for commercialization and drove the strategic sale process, which resulted in the $960M acquisition by Angelini Pharma.
Previously, Greg was Chief Financial Officer at Axovant Sciences, Inc., where he oversaw finance, accounting, investor relations and business development. At Axovant, he was the principal financial and accounting officer for SEC purposes and was responsible for three public financings, a private placement, and a venture debt financing.
Before becoming Chief Financial Officer of Axovant, Greg spent 15 years as an early-stage healthcare venture capitalist at CHL Medical Partners. He was the founding chief executive officer and sole Series A investor in Amicus Therapeutics where he remained a board member and member of the audit committee through its IPO in 2009. Prior to graduate school, Greg was a financial analyst in Morgan Stanley & Co.’s healthcare corporate finance group.
Greg holds an MD degree from Harvard Medical School, an MBA from Harvard Business School, and an AB in economics from Harvard College.
